TABLE 2.

Statistically significant reduced pathways due to bleeding based on robust multichip average preprocess

Pathway	Name	P	q	Set size	Path size
rno04110	Cell cycle	2.38E−10	6.46E−08	121	127
rno04510	Focal adhesion	2.14E−06	2.90E−04	185	206
rno04144	Endocytosis	5.50E−06	4.97E−04	262	290
rno00230	Purine metabolism	1.10E−05	5.17E−04	166	182
rno03030	DNA replication	1.18E−05	5.17E−04	32	36
rno04142	Lysosome	1.31E−05	5.17E−04	119	129
rno05206	MicroRNAs in cancer	1.33E−05	5.17E−04	133	143
rno03040	Spliceosome	1.56E−05	5.27E−04	112	138
rno00240	Pyrimidine metabolism	4.77E−05	1.34E−03	95	107
rno04151	PI3K-Akt signaling pathway	4.95E−05	1.34E−03	308	336
rno05200	Pathways in cancer	7.00E−05	1.71E−03	371	400
rno05205	Proteoglycans in cancer	7.58E−05	1.71E−03	192	205
rno04068	FoxO signaling pathway	1.16E−04	2.43E−03	125	136
rno05166	HTLV-I infection	1.81E−04	3.50E−03	256	295
rno04115	p53 signaling pathway	2.26E−04	4.09E−03	64	71
rno05203	Viral carcinogenesis	2.72E−04	4.45E−03	194	239
rno04611	Platelet activation	2.88E−04	4.45E−03	112	127
rno03008	Ribosome biogenesis in eukaryotes	2.96E−04	4.45E−03	79	88
rno05169	Epstein-Barr virus infection	3.54E−04	5.00E−03	195	231
rno04120	Ubiquitin-mediated proteolysis	3.69E−04	5.00E−03	128	141
rno05220	Chronic myeloid leukemia	4.05E−04	5.16E−03	68	76
rno03013	RNA transport	4.19E−04	5.16E−03	144	165
rno04810	Regulation of actin cytoskeleton	4.79E−04	5.57E−03	202	221
rno04670	Leukocyte transendothelial migration	5.12E−04	5.57E−03	111	120
rno04512	ECM-receptor interaction	5.14E−04	5.57E−03	75	84
rno05322	Systemic lupus erythematosus	5.37E−04	5.60E−03	87	136
rno04210	Apoptosis	6.77E−04	6.79E−03	119	141
rno05100	Bacterial invasion of epithelial cells	1.05E−03	1.00E−02	71	81
rno05161	Hepatitis B	1.07E−03	1.00E−02	122	139

ECM, extracellular matrix; HTLV-I, human T-lymphotropic virus I.